ASP 6294

Drug Profile

ASP 6294

Alternative Names: ASP6294

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Antibodies; Urologics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Interstitial cystitis

Most Recent Events

  • 18 Sep 2017 Astellas Pharma plans the SERENITY phase II trial for Interstitial cystitis (NCT03282318)
  • 30 Apr 2017 Phase-II clinical trials in Interstitial cystitis in Europe (unspecified route) (Astellas Pharma pipeline, April 2017)
  • 09 Jan 2017 Astellas Pharma completes a phase-I trial in Interstitial cystitis (In volunteers) in United Kingdom (IV, SC) (NCT02681861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top